T his study assessed the effects of tesaglitazar (0.5 or 1 mg/day), a dual peroxisome proliferator-activated receptor α/γ agonist, when added to maximally tolerated metformin (2-2.5 g/day) in patients with poorly controlled type 2 diabetes. The primary end point of this 24-week, randomised, placebo-controlled study was the absolute change from baseline in glycosylated haemoglobin (HbA 1C ).
Introduction
Historically, hyperglycaemia has been considered the characteristic feature of type 2 diabetes and has, therefore, formed the main focus of treatment. However, current treatment guidelines for type 2 diabetes also emphasise lipid control in recognition of the contribution of abnormal lipid profiles to the increased cardiovascular disease risk in diabetes. 1 It is also apparent that other important contributors to atherosclerosis and cardiovascular disease (such as oxidative stress, local and systemic inflammation, abnormal coagulation and fibrinolysis) are present in type 2 diabetes. 2 Metformin lowers blood glucose by reducing hepatic glucose production and enhancing insulin sensitivity. 3 However, the agent is limited by its inability to maintain glycaemic control, 4, 5 while its effects on all components of the atherogenic dyslipidaemia of type 2 diabetes remain inconclusive. 6 Thus, polypharmacy is often required to reach target glycaemic goals and to improve the abnormal lipid profile of type 2 diabetes substantially.
Dual peroxisome proliferator-activated receptor (PPAR)α/γ activation is a rational approach to improve the co-existing metabolic abnormalities of type 2 diabetes. PPARs are transcription factors that play a central role in glucose and lipoprotein metabolism. PPARα agonism (by fibrates, for example) induces fatty acid catabolism in the liver and skeletal muscle, and thus lowers triglyceride (TG) levels and increases levels of high-density lipoprotein cholesterol (HDL-C). 7, 8 In comparison, PPARγ agonism (by thiazolidinediones [TZDs], for example) promotes differentiation of pre-adipocytes, leading to a decrease in circulating levels of free fatty acids (FFA) and ultimately to decreased insulin resistance. 9 According to recent investigations, TZDs may offer more durable glycaemic control than other glucoselowering agents, 10 perhaps via their proposed ability to preserve beta-cell function. 11, 12 Tesaglitazar, a dual PPARα/γ agonist, was shown in earlier monotherapy studies to improve glycaemic control and lipid abnormalities in insulin-resistant, non-diabetic patients 13 and in patients with type 2 diabetes. 14 This study (GALLANT 8) was one of several phase III studies that evaluated the efficacy and safety of tesaglitazar in type 2 diabetes. In this study, the efficacy and safety of add-on tesaglitazar were assessed in patients with type 2 diabetes in whom metformin alone failed to achieve adequate glycaemic control. The study presents data considered in the decision to halt the clinical development of tesaglitazar.
Methods GALLANT 8 (D6160C00031; clinicaltrials.gov identifier NCT00251953) was a 24-week, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy, safety and tolerability of tesaglitazar 0.5 and 1 mg once daily as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. This multinational study was conducted in 114 centres across the Asia-Pacific region, Canada and Europe.
The study conformed to the guidelines of the Declaration of Helsinki (version dated October 2000) and was approved by an appropriate Institutional Review Board at each study centre. Patients provided their written informed consent before entering the study.
Patients
Patients enrolled in this study were men and women (if women, post-menopausal or using adequate contraception) aged 18 years or older with poorly controlled type 2 diabetes who were receiving combination therapy or monotherapy with oral antidiabetic medications (glycosylated haemoglobin [HbA 1C ] > 7% if previously on monotherapy, but < 10%; fasting plasma glucose [FPG] < 13.3 mmol/L or 240 mg/dL). Key exclusion criteria included recent treatment with TZDs or fibrates, and New York Heart Association (NYHA) Class III or IV heart failure or unstable Class I or II (i.e. those patients not considered to be in a stable condition by the study investigators).
Study design
Following a two-week enrolment period, during which all oral antidiabetic medications were discontinued, with the exception of metformin, patients entered a six-week metformin titration phase. In the titration phase, metformin was increased to the maximum tolerated dose (2-2.5 g/day) in order to achieve FPG < 7.0 mmol/L or 126 mg/dL. During this period, patients monitored their FPG every second morning and continued to monitor their plasma glucose and to record any hypoglycaemic events in their diaries. The dose of metformin used at enrolment was maintained for patients who had previously received metformin and had a FPG < 7.0 mmol/L, but was increased by 0.5 g in patients with FPG > 7.0 mmol/L. For patients who had not previously received metformin, the medication was initiated at 1.5 g/day and increased stepwise by 0.5 g in those with a FPG > 7.0 mmol/L.
At the end of the titration period, patients who remained insufficiently controlled (with HbA 1C 7-10%; FPG 7.0-11.7 mmol/L) on maximally tolerated metformin treatment of 2-2.5 g/day proceeded to single-blind treatment with placebo in addition to metformin for two weeks. Patients were then randomised to 24 weeks of double-blind treatment with tesaglitazar (0.5 or 1 mg) or placebo once daily as addon treatment to metformin. It was recommended to investigators that the metformin dose achieved on completion of the titration period be maintained throughout the study.
Other medications (except antidiabetic agents, fibrates and probenecid) were permitted during randomised treatment.
Patients were instructed to self-monitor and record plasma glucose (at least once a week) and any hypoglycaemic events, and were counselled on dietary and lifestyle modifications during the study.
On completion of the trial, patients who did not continue in a long-term extension study attended one follow-up visit during a three-week period. Metformin treatment only was continued throughout the three-week follow-up period.
Assessments
Assessments of efficacy and safety measures were conducted every four weeks at regularly scheduled patient visits.
Efficacy end points
The primary study end point was the absolute change in HbA 1C from baseline to the end of the 24-week randomised treatment period. Secondary end points included the absolute change from baseline to the end of the randomised treatment period in FPG as well as the relative (%) change from baseline to the end of randomised treatment in insulin, lipid and lipoprotein variables (TG, total cholesterol [TC], HDL-C, non-HDL-C, low-density lipoprotein cholesterol [LDL-C], apolipoproteins [apoB, apoA-I]), and C-reactive protein (CRP; assessed with the high sensitivity [hs]-CRP test). The analyses were performed by Covance Central Laboratory Services LP (Indianapolis, IN, US) and full details are described elsewhere. 15 Safety Safety assessments encompassed adverse events (AEs), including serious AEs (SAEs), as well as laboratory tests (haematology, clinical chemistry and urinalysis), vital signs, cardiovascular assessment (including evaluation of signs and symptoms of congestive heart failure [CHF]) and general physical examination. Also assessed were hypoglycaemic events (plasma glucose level < 3.5 mmol/L or 54 mg/dL), which were defined in accordance with guidance from the Committee for Proprietary Medicinal Products (CPMP). 16 Hypoglycaemic events were classified as major events if they were symptomatic or required external assistance due to severe impairments in consciousness or behaviour. Symptomatic or asymptomatic events that did not require external assistance were classified as minor hypoglycaemic events.
Statistical methods
Sample size was determined using the primary end point (change from baseline in HbA 1C ). Using a two-sided t-test at a significance level of 0.05 and assuming a standard deviation of 1.4%, 165 patients were required in each treatment arm to detect a difference of 0.5% between treatment groups.
All efficacy measures were analysed using the intentionto-treat (ITT) population (i.e. patients with at least one observation during randomised treatment). The safety population comprised all patients who received at least one dose of study medication and for whom post-dose data were available.
Changes from baseline to study end for efficacy variables were evaluated using a fixed-effect analysis of covariance (ANCOVA). All efficacy variables except HbA 1C and FPG were log-transformed prior to ANCOVA analysis. For analysis of HbA 1C , TG, HDL-C and non-HDL-C, a Bonferroni-Holm procedure was used to control the overall significance level at 0.05. 17 For all other variables, the overall significance levels were not adjusted for multiplicity and the results of the statistical testing must be considered as supportive information. Descriptive statistics were used for analyses of safety data.
Results

Patients
Of the 1,607 patients enrolled into the study, 590 patients were randomised to add-on treatment with tesaglitazar 0.5 mg/day (n=194), tesaglitazar 1 mg/day (n=196) or placebo (n=200). The treatment groups were similar with respect to the overall number of discontinuations from the study (n=31 for tesaglitazar 0.5 mg; n=31 for tesaglitazar 1 mg; n=37 for placebo). A total of 252 patients (43%) attended the three-week follow-up visit and 295 patients (50%) transferred to the open-label extension study.
Baseline and demographic characteristics of patients were generally similar between treatment groups (table 1). The mean duration of diabetes was somewhat longer in the placebo group (7.8 years vs. 6.2 and 6.6 years for the 0.5 and 1 mg tesaglitazar groups, respectively), but this is unlike-ly to have influenced the safety and efficacy results. Notably, more than half (53%) of the patients were using concomitant statin treatment throughout the study.
Efficacy
Significant reductions in the primary end point, HbA 1C , from baseline after 24 weeks of add-on treatment were observed GALLANT 8 STUDY . As presented in figure 1 , HbA 1C levels were reduced at week 4 and continued to decrease until the end of the randomised treatment phase. Add-on tesaglitazar treatment also improved secondary measures of efficacy (table 2) . At 24 weeks, tesaglitazar-treated patients differed significantly from placebo-treated patients in reductions from baseline in FPG and insulin (p<0.0001). Furthermore, mean change from baseline in TG, HDL-C and non-HDL-C levels demonstrated significant improvements for both tesaglitazar treatment groups, compared with placebo (p<0.0001). Add-on treatment with tesaglitazar did not significantly lower LDL-C levels.
Dose-related improvements in mean apoB and apoA-I levels differed significantly from placebo at 24 weeks for both tesaglitazar treatment groups (p<0.028), as did decreases in the mean levels of CRP in the tesaglitazar 1 mg group (p=0.013).
Safety
Two deaths (one cardiac death and one coronary artery thrombosis) were reported during add-on treatment with tesaglitazar 1 mg. Neither death was considered to be related to the study medication. The proportions of patients experiencing AEs were generally similar among the treatment groups (table 3) . With the exception of peripheral oedema, there were no treatment-or dose-related differences in the types of AEs reported between groups. Of the 31 SAEs reported in 29 patients during the randomised treatment phase, similar frequencies of SAEs were observed in the placebo plus metformin group (5.5%), compared with tesaglitazar 0.5 and 1 mg groups (5.2% and 4.1%, respectively). None of the SAEs reported in the tesaglitazar treatment groups was considered to be related to the study medication. Discontinuation of the study medication due to AEs was reported for 3.6% and 2.1% of patients in the tesaglitazar 0.5 and 1 mg groups, GALLANT 8 STUDY Data are presented as n (%) respectively, and for 2.5% of patients in the placebo plus metformin group. There were no confirmed cases of CHF among the treatment groups. During randomised treatment, pre-defined cardiovascular events (i.e. events related to cardiac ischaemia, stroke or ventricular arrhythmias) were experienced by 2.6% and 4.6% of patients in the tesaglitazar 0.5 and 1 mg groups, respectively, and by 1.0% of patients in the placebo plus metformin group. Cardiovascular events reported in these patients were angina pectoris, chest discomfort, myocardial infarction, myocardial ischaemia, cardiac death, cardiac disorder, chest pain, coronary artery disease, coronary artery thrombosis and absent pulse. Peripheral oedema was a more common AE among treatment groups, with the highest incidence reported in the tesaglitazar 1 mg group (table 3) . Both add-on tesaglitazar treatment groups demonstrated a dose-related increase in weight from baseline to end of randomised treatment (mean change + SD of 1.16+2.85 kg for tesaglitazar 0.5 mg plus metformin and 2.13+2.98 kg for tesaglitazar 1 mg plus metformin), compared with a small decrease in the placebo plus metformin group (-0.82+2.59 kg). There were no major changes in the waist-to-hip ratio from baseline in the three treatment groups (table 2) .
Mean levels of serum creatinine increased in dosedependent fashion from baseline following add-on treatment with tesaglitazar (table 4). These changes in serum creatinine stabilised after 12 weeks in the majority of patients. Reversibility could not be fully evaluated due to the limited data available at follow-up (table 4) . However, in the sample of patients for whom follow-up data were available, serum creatinine values returned towards baseline in the tesaglitazar 0.5 mg group. There were no accompanying abnormalities in urinalysis tests for protein or haematuria. One patient in the placebo plus metformin group demonstrated an increase from baseline in serum creatinine greater than 50% and 1.5 times above the upper limit of normal during randomised treatment. GALLANT 8 STUDY Key: ALP = alkaline phosphatase; ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; GGT = gamma glutamyl transferase; Hb = haemoglobin Add-on treatment with tesaglitazar resulted in decreases from baseline in mean haemoglobin (Hb) and neutrophil levels (table 4) . The small sample population available for follow-up analysis restricted a full evaluation of reversibility, but the changes in Hb (in the tesaglitazar 1 mg group only) and neutrophils observed at follow-up indicated a return towards baseline levels (table 4) . During the randomised treatment period, Hb levels fell below a pre-specified threshold (< 100 g/L) in 16 patients (six patients each in the tesaglitazar 0.5 and 1 mg groups and four patients in the placebo group), while 10 patients had absolute neutrophil counts (ANC) below a pre-specified level of 1.5 x 10 9 /L (seven patients in the tesaglitazar 0.5 mg group, two patients in the tesaglitazar 1 mg group and one patient in the placebo group). In the majority of patients for whom follow-up data were available, absolute neutrophil counts tended to approach baseline levels. Dose-dependent decreases in alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and gamma glutamyl transferase (GGT) were also apparent during add-on treatment with tesaglitazar, while aspartate aminotransferase (AST) changed little in response to treatment (table 4). These variables tended to return towards baseline values in the limited sample population available for follow-up analysis.
Hypoglycaemic events were experienced by five patients (nine events) and by six patients (eight events) in the tesaglitazar 0.5 mg and 1 mg treatment groups, respectively, compared with none in the placebo group. Major hypoglycaemic events occurred at similar frequencies within each tesaglitazar treatment group (four in each group).
Discussion
In this multinational study of patients with type 2 diabetes poorly controlled on metformin alone, add-on treatment with either 0.5 or 1 mg of tesaglitazar significantly improved HbA 1C levels after 24 weeks of therapy, compared with placebo plus optimised metformin. The efficacy of add-on treatment with tesaglitazar in improving glycaemic control beyond that of metformin alone was further supported by the significant reductions in FPG and insulin.
Consistent with earlier outcomes from insulin-resistant patients and patients with type 2 diabetes treated with tesaglitazar alone, 13, 14 both tesaglitazar treatment groups improved TG, HDL-C and non-HDL-C levels. There were no marked changes in the lipid profile in the placebo group. Significant dose-related improvements in apoB and apoA-I levels were observed following add-on treatment with tesaglitazar. Studies of cardiovascular risk, such as the Apolipoprotein-related MOrtality RISk (AMORIS) study, have documented the significant contribution of high apoB levels to increased cardiovascular risk as well as the cardioprotective effects of high apoA-I levels. 18, 19 Furthermore, the lipid-lowering effects of tesaglitazar were notable in a population in which approximately half were receiving statin therapy, and support evidence that statins alone do not fully ameliorate the dyslipidaemia observed in diabetes. 20, 21 Subclinical inflammation is a risk factor for cardiovascular disease. CRP may play an integral role in systemic inflammation and the development of atherosclerosis, 22 or it may act as a risk marker. Metformin has been shown to lower CRP levels in patients with type 2 diabetes. 23 In the current study, CRP levels were lowered further on addition of tesaglitazar 1 mg to metformin. TZDs have also been shown to lower CRP, 24 and it has been suggested that increases in CRP may be partly related to insulin resistance. 25 Thus, a common action may underlie the effects of all these agents on CRP.
The underlying mechanisms for the effects of PPARα and PPARγ agonism on glucose homeostasis, lipid metabolism and inflammation are well characterised. 7, 8, 26 The improvements in the efficacy measures observed with tesaglitazar are compatible with expectations of the effects of dual PPARα/γ agonism.
Peripheral oedema and weight gain, acknowledged side effects of PPARγ agonism, 9, 27, 28 were more common in the tesaglitazar 1 mg group. Weight gain with PPARγ treatment may be due, in part, to fluid retention 29, 30 and may be partly a consequence of increased deposition of FFA in subcutaneous adipose tissue, which eventually manifests as improved glycaemic control. 31 As with other studies that have found metformin to be weight neutral or to cause modest reductions in weight, a slight decrease in weight was observed with placebo plus metformin in the current study. 32 Congestive heart failure is a recognised, albeit rare, side effect of PPARγ agonists. 9, 27 There were no confirmed cases of CHF in any treatment group in the current study, despite the higher frequency of peripheral oedema with add-on tesaglitazar treatment.
Treatment-and dose-related decreases in haemoglobin and ANC were observed in this study. Reductions in these haematology measures are well-known effects of agents that modulate PPARγ, including tesaglitazar. 9, 13, 14, 33 The mechanism underlying such changes has not been fully defined. However, in the small numbers followed up here, these changes indicated a return towards baseline levels.
The dose-dependent increases in mean serum creatinine levels observed in this study have also occurred in previous tesaglitazar studies. 13, 14, 34 Measurements from 12 weeks onward appeared to indicate that serum creatinine levels were stabilising. Moreover, given the caveat that half of the patients who completed the study entered the open-label extension study, the values at follow-up suggest that the elevations in serum creatinine were reversible. The follow-up time may have been too short for complete reversibility of drug-induced changes, as indicated by a bigger deficit remaining in the tesaglitazar 1 mg group at the three-week follow-up. As in previous studies, 13, 14, 34 the increases in serum creatinine were not associated with indicators of renal damage. Reversible increases in serum creatinine levels have been observed with some fibrates. [35] [36] [37] For example, increases in serum creatinine levels of 10-12 µmol/L were observed in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. 37 This suggests an involvement of PPARα but the mechanisms underlying this effect of tesaglitazar are still unknown.
As observed in previous tesaglitazar studies, 14 there were small decreases in ALT, ALP, GGT and bilirubin following treatment with tesaglitazar. The changes in ALT and GGT are possibly the result of reductions in hepatic fat content and insulin resistance. 38 There were more reports of hypoglycaemic events with tesaglitazar treatment than with placebo. Previous studies of tesaglitazar or metformin alone have not indicated a high incidence of hypoglycaemic events, 14, 39 suggesting that the enhanced glycaemic control obtained with both agents increased the vulnerability of some patients to hypoglycaemic events.
Summary
Patients with type 2 diabetes who were insufficiently controlled on metformin showed significant improvements in glycaemic control and multiple components of atherogenic dyslipidaemia with add-on treatment with tesaglitazar at 0.5 or 1 mg per day. In line with previous monotherapy studies, 13, 14 tesaglitazar therapy was associated with increases in serum creatinine levels and decreases in the levels of Hb and absolute neutrophil counts. Upon consideration of the present data and findings from other tesaglitazar studies, it was judged that the overall benefit-risk profile of tesaglitazar did not provide additional benefit to patients compared with other currently available therapy. Consequently, the clinical development of tesaglitazar was discontinued. Nevertheless, this study has highlighted the potential of add-on treatment with a dual PPARα/γ agonist in patients with type 2 diabetes who have inadequate glycaemic control. It is hoped that the findings from this study will aid the development of new treatments for type 2 diabetes.
